INTRODUCTION
Despite the considerable success of current therapies for childhood T-cell acute lymphoblastic leukemia (T-ALL), induction failure, disease relapse and treatment-related complications represent considerable challenges. More effective and less toxic therapies are necessary to improve outcome and the therapeutic index. In the post-genome era, a feasible strategy is to target molecules and pathways that play critical roles in the biology of the tumor, a strategy validated by the success of STI-571 in chronic myelogenous leukemia and by the promising results of clinical trials with other signaling inhibitors. [1] [2] [3] An inherent obstacle is the availability of malignant T-cells in numbers sufficient to perform the signaling experiments necessary for target identification, drug screening and pre-clinical validation.
We have previously shown that interleukin-7 (IL-7) promotes the survival and proliferation of T-ALL cells by modulating Bcl-2 expression and cell cycle progression through downregulation of the cdk inhibitor p27 Kip1 . 4 IL-7 has been implicated in normal Tcell survival and proliferation, and, in immature T-cells, plays a non-redundant anti-apoptotic role by upregulating Bcl-2 expression. 5 Mice deficient in IL-7 or lacking the IL-7 receptor are lymphopenic due to a defect in T-cell expansion at an early stage of differentiation, and the few mature T-cells that develop are functionally impaired. [5] [6] [7] Importantly, IL-7 has been implicated in leukemogenesis, since IL-7 transgenic mice develop lymphoid malignancies. 8 Malignant T-ALL cells express functional IL-7 receptors, 9 and IL-7 stimulates blast colony formation and DNA synthesis, suggesting that it may play an important regulatory role in the pathophysiology of T-ALL. 9, 10 Finally, IL-7 is produced in the bone marrow (BM) and thymic stroma 11 and therefore is present in the microenvironments where malignant T-cells develop.
In an effort to develop better tools for anti-leukemia target validation in T-ALL, we have established a T-cell Acute-Leukemia IL-7-dependent cell line (TAIL7) derived from the leukemia cells of a 7-year old male patient. After more than 12 months in continuous culture, TAIL7 cells maintain several features also found in the patient's primary malignant cells, including: 1) the monoclonal TCR-γ rearrangement; 2) the immunophenotype of T-cell blasts arrested at an immature thymocyte stage of maturation -pre-T ALL; 3) the proliferative response to IL-7 and IL-4; 4) the engraftment and establishment of leukemia in NOD/SCID mice; and importantly, 5) the signaling events triggered by IL-7 stimulation, namely downregulation of p27 kip1 , and hyperphosphorylation of the retinoblastoma protein (Rb).
Finally, using a JAK3-specific inhibitor, we demonstrate that blockade of signaling pathways triggered by IL-7 significantly abrogates the proliferation and survival of TAIL7 cells. Our results indicate that TAIL7 may constitute a biologically-relevant tool for the identification of molecular targets and the development of novel therapeutic agents for T-ALL.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From supplemented with 10% FBS (RPMI-10) and 10ng/ml of recombinant IL-7 (Endogen, Woburn, MA). After 9 days in culture at 37ºC, 5% CO 2 , dead cells were removed using the MACS Dead-cell Removal ® kit (Miltenyi Biotec, Auburn, CA), and viable cells recultured under similar conditions. This strategy was employed for the initial three cycles of leukemia T-cell culture and IL-7-mediated expansion. For further passages, every 7 to 9 days, viable leukemia cells were separated by density centrifugation, and replated in IL-7. TAIL7 cells have been maintained on IL-7 continuous culture for more than a year. To confirm IL-7-responsiveness and dependency, viability and proliferation assays were performed periodically. When necessary, viable TAIL7 cells were starved in either RPMI-10 for 5-10 days or RPMI without FBS for 2-3 days prior use. For signaling experiments, cultured cells were washed twice with PBS and incubated for 15 min. at 37°C with pre-warmed PBS alone or with IL-7. The reaction was stopped by placing samples on ice and adding ice-cold PBS.
MATERIALS AND METHODS

T-cell ALL
Cells were washed twice with cold PBS and whole cell lysates prepared.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Immunophenotype. Primary leukemia cells and TAIL7 cells were phenotyped using standard methodology. 12 The fluorochrome-conjugated mAbs (Table 1) were obtained from BD Pharmingen (San Diego, CA) and Beckman-Coulter (Miami, FL). Samples were analyzed in a Coulter Elite or XL flow cytometer (Beckman-Coulter), and data were acquired as listmode files. At least 5,000 positive events were acquired for each sample.
Clonality Assessment and Cytogenetics Analysis. The characterization of immunoglobulin heavy chain (IgH), T-cell receptor (TCR), and TAL1 gene rearrangements on the primary leukemia and TAIL7 cells was performed using previously described primers and protocols. 13, 14 Sequencing was performed using the BigDye Terminators Cycle Sequencing kit (Applied Biosystems, Foster City, CA). V, D, and J segments were identified using the ImMunoGeneTics (IMGT) database. 15 Cytogenetic analysis was performed using a standard G-banding technique. The consensus karyotypes were derived by analysis of more than 15 metaphase cells.
Engraftment into NOD/SCID Mice. To assess tumorigenicity, viable TAIL7 cells (5x10 6 cells) were transplanted IV into irradiated NOD/SCID mice. Animals were sacrificed when moribund. Blood was collected via retro-orbital puncture and bone marrow was extracted by flushing of long bones. Femurs, spleen, liver, kidneys and, when possible, thymus and lymph nodes were collected for histological analysis.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From Proliferation assays. TAIL7 cells were cultured in flat-bottom 96-well plates at 4x10 5 cells/well, in standard RPMI-10 or in the presence of IL-7 (10ng/ml), IL-2 (100U/ml), IL-4 (10ng/ml), IL-9 (50U/ml), IL-15 (20ng/ml) or PHA (1µg/ml) + PMA (1ng/ml). Cultures were performed in triplicates for the indicated time points. To assess DNA synthesis, 3 HThymidine (1µCi/well) was added for 16 hrs prior to cell harvest, and measured using a liquid scintillation counter. Proliferation index (P.Index) was calculated as: P.Index = (mean cpm for each experimental condition) / (mean cpm for medium alone).
Cell Viability and Activation. Quantitative determination of cell viability was performed using an Annexin V-based apoptosis assay (R&D Systems, Flanders, NJ 
RESULTS
Establishment of an IL-7-Dependent Leukemia T-Cell Line
The very high rate of spontaneous apoptosis and lack of significant in vitro expansion of leukemia T-cells represent considerable obstacles to the study of the biology of T-ALL and the evaluation of novel therapeutic agents. To circumvent these limitations, we established a 
IL-7 Induces TAIL7 Cell Proliferation, Activation, Survival and Cell Cycle Progression
We next evaluated whether TAIL7 cells maintain the pattern of responsiveness to IL-7
and other γ c -signaling cytokines observed for their parental primary leukemia cells. TAIL7 cells showed a robust proliferative response to IL-7 and a weaker response to IL-4 ( Figure   2A ). No proliferation was observed in response to IL-2, IL-9 or IL-15 ( Figure 2A ). Also, TAIL7 cells failed to proliferate when cultured with PHA plus PMA, which instead resulted in lower levels of 3 H-thymidine incorporation ( Figure 2A) . Importantly, the response of TAIL7 cells to these cytokines and mitogens was in complete concordance with the pattern observed for the parental leukemia cells from which this cell line was derived ( Figure 2B ).
As expected, culture of TAIL7 cells with IL-7 resulted in an increased percentage of cells in S-and G2/M phases of the cell cycle ( Figure 3A) , and in increased cell size and complexity, as illustrated by the physical changes detected by flow cytometry ( Figure 3B ; FSC versus SSC signals). Finally, stimulation of TAIL7 cells with IL-7 promoted cell viability, which was more pronounced after more stringent pre-culture starvation conditions ( Figure 3C ).
Again, these findings are consistent with observations using the patient's primary leukemia cells, although the effect of IL-7 on survival of the parental leukemia cells was even more pronounced than that observed for the cell line (average 30% increase on viability at 96 hours versus 17% for the TAIL7 cells). Strikingly, these functional responses triggered by the IL-7-stimulation of TAIL7 cells are equivalent not only to those observed for the parental leukemia cells but also to those observed in all the IL-7-responsive primary leukemia samples previously tested (70% of the patients analyzed; Reference 4).
TAIL7 Cells Are Tumorigenic
To determine tumorigenicity, TAIL7 cells were transplanted IV into irradiated NOD/SCID mice (5x10 6 viable cells/mouse). In all animals tested (n=6), TAIL7 cells engrafted and developed into a leukemia involving multiple organs. Animals were moribund and sacrificed at 64.3 ± 2.3 days after cell injection (range 63 -67 days). Histological analyses showed, in all animals, that the BM was packed with leukemia cells (Figure 4A , B).
Splenomegaly and enlarged lymph nodes were a common occurrence in the transplanted animals with large numbers of leukemia cells present in the spleen and lymph nodes ( Figure   3C , D, E). Leukemia cells were also observed invading the liver and kidneys ( Figure 4F , G).
No evidence of thymus enlargement or mediastinal mass was observed. Importantly, the time-interval of TAIL7 growth and leukemia development in NOD/SCID mice was similar to that observed for primary leukemia cells, which is longer than that observed for established, stimuli-independent leukemia cell lines (data not shown).
IL-7-Triggered Signaling Events on TAIL7 Cells
To further investigate whether the TAIL7 cell line is a reliable substitute for primary leukemia cells, we have compared the signaling events triggered by IL-7 stimulation in TAIL7 cells with those of their parental leukemia cells. This is particularly important as TAIL7 cells are to be employed as surrogate 'primary' leukemia T-ALL cells for the identification of signaling molecules that may constitute therapeutic targets.
We evaluated the impact of IL-7 on the expression of the cell cycle regulator p27 kip1 , since we have previously demonstrated that IL-7 induces cell cycle progression in T-ALL cells through down-modulation of the activity of this cdk inhibitor. 4 As shown in Figure 5A , we observed a marked downregulation of p27 kip1 in TAIL7 cells following IL-7 stimulation.
IL-7 also induced upregulation of the hyperphosphorylated form of the Retinoblastoma protein (Rb), a critical substrate of cyclin/cdk activity, indicating that cells are committed to cell cycle progression ( Figure 5B ). An identical pattern of IL-7-mediated p27 kip1 downregulation ( Figure 5C ) and hyperphosphorylation of Rb (data not shown) was found in parental primary leukemia cells.
One of the earliest events in IL-7 signaling is the activation of the γ c -associated protein tyrosine kinase JAK3. 25 As shown in Figure 6A , IL-7 mediates tyrosine phosphorylation of JAK3 in TAIL7 cells, thus confirming that a functional IL-7 receptor complex exists in these cells. We further assessed the capacity of IL-7 to trigger the JAK/STAT, MEK/Erk and PI3K/Akt pathways, which are common mediators of cytokine signaling. As shown in Figure   6B , there is a striking upregulation of phospho-STAT5, phospho-Erk1/2 and phospho-Akt upon IL-7 stimulation of TAIL7 cells, thus indicating that all three pathways are activated by IL-7.
Significantly, the cell cycle-related events triggered by IL-7 stimulation of TAIL7 cells are consistent with those observed using not only the parental leukemia cells but also any of the IL-7-responsive T-ALL specimens previously tested. 4 For
org From
The JAK3-Specific Inhibitor WHI-P131 Abolishes the IL-7-Promoted Proliferation and
Survival of TAIL7 Cells
Since the JAK/STAT pathway is activated by IL-7 stimulation of TAIL7 cells (Figure 6 ), we evaluated the effect of the JAK3-specific inhibitor WHI-P131 on TAIL7 cell survival and proliferation. WHI-P131 is a dimethoxyquinazoline derivative that specifically inactivates JAK3, but not other JAK-family members, by interacting with its catalytic site. 17 It has been shown previously that WHI-P131 induces the apoptosis of JAK3-positive B-lineage leukemia cell lines (optimal dose, 100 µM) but not JAK3-negative cells. 17 WHI-P131 completely abrogates the stimulatory effect of IL-7 on TAIL7 cells, inhibiting both cell proliferation ( Figure 7A ) and survival ( Figure 7B ). This inhibitory effect was dose-dependent ( Figure 7A and data not shown) and demonstrated that the specific blockade of JAK3 effectively abrogates the stimulatory effect of IL-7. As shown in Figure 7 , at 100µM, the WHI-P131-mediated inhibition of TAIL7 cells surpassed that observed in absence of IL-7, suggesting that some degree of constitutive activation of JAK3 exists in TAIL7 cells. This finding is in agreement with the low basal level of JAK3 tyrosine phosphorylation observed in unstimulated TAIL7 cells, which was upregulated by IL-7 ( Figure 6A ). Despite the apparent constitutive activation of JAK3, we did not find any evidence of constitutive phosphorylation of its direct target STAT5 ( Figure 6B ). Notwithstanding, we observed that in TAIL7 cells,
WHI-P131 markedly reduced the IL-7-mediated phosphorylation of STAT5 (data not shown).
We have previously demonstrated that the IL-7-mediated stimulation of primary T-ALL cells is inhibited by the mTOR-specific inhibitor Rapamycin. 4 On TAIL7 cells, we observed that Rapamycin also abrogates IL-7-promoted survival ( Figure 7C ), mimicking our findings on primary leukemia T-cells. Finally, we evaluated the effects on TAIL7 cell survival of two chemotherapeutic drugs known for their potent cytotoxic activity on T-ALL cellsDexamethasone and Doxorubicin. At concentrations cytotoxic to primary leukemia T-cells, 26 ,27 both drugs promote significant apoptosis of TAIL7 cells ( Figures 7C) . Strikingly, the effect of the JAK3-specific inhibitor WHI-P131 on TAIL7 is superior to that caused by the chemotherapeutic drugs ( Figure 7D ), and mimics its inhibitory activity on IL-7-promoted proliferation and survival of primary T-ALL cells (data not shown). These findings indicate that TAIL7 cells retain their sensitivity to conventional drugs and are useful surrogates of primary leukemia T-cells for the evaluation of novel drugs with therapeutic potential.
T-Cell Oncogene Expression and DNA Fingerprinting of TAIL7 Cells
To further characterize TAIL7 cells, we have studied the expression of the T-cell with other cell line(s). 29 The screening and validation of agents that inhibit signaling molecules or pathways in a specific manner particularly requires cell lines that preserve the patterns of responsiveness to microenvironmental stimuli and the signaling pathways pathway, to promote the occurrence of leukemia.
In conclusion, we established a cell line -TAIL7, derived from a T-ALL patient that is dependent upon IL-7 and that retains the IL7-triggered engagement of defined functional and signaling events observed not only in their parental leukemia cells but also in IL-7-responsive primary leukemias, which account for most T-ALL cases. 4 This novel cell line is presently being used as a model system for the dissection of the signaling pathways implicated in T-ALL survival and growth, the identification of therapeutic targets and, most importantly, for the screening of putative anti-leukemia agents. Since TAIL7 reflects the cellular and molecular properties of primary T-cell leukemia, it represents a valuable research tool. and BHLHB1 were determined using quantitative RT-PCR analysis of TAIL7 For STR, the allele nomenclature is shown in parenthesis. For Amelogenin, the sex chromosome is indicated in parenthesis.
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